|
SK286640B6
(sk)
*
|
1998-06-19 |
2009-03-05 |
Pfizer Products Inc. |
Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
ATE423120T1
(de)
*
|
2000-06-26 |
2009-03-15 |
Pfizer Prod Inc |
Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
|
|
JP2004509876A
(ja)
|
2000-09-20 |
2004-04-02 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
４−アミノ−キナゾリン
|
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
|
DE10063294A1
(de)
*
|
2000-12-19 |
2002-07-04 |
Aventis Pharma Gmbh |
Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
|
|
US20040102455A1
(en)
*
|
2001-01-30 |
2004-05-27 |
Burns Christopher John |
Method of inhibiting kinases
|
|
DE60206363T2
(de)
|
2001-02-12 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
6-substituierte pyridopyrimidine
|
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
ES2266553T3
(es)
|
2001-06-29 |
2007-03-01 |
Ab Science |
Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
|
|
WO2003003006A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
New potent, selective and non toxic c-kit inhibitors
|
|
WO2003002109A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
|
ES2274993T3
(es)
|
2001-06-29 |
2007-06-01 |
Ab Science |
Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
|
|
JP2004537542A
(ja)
*
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
US7323469B2
(en)
|
2001-08-07 |
2008-01-29 |
Novartis Ag |
7H-pyrrolo[2,3-d]pyrimidine derivatives
|
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
|
PY0228255A
(es)
|
2001-12-06 |
2004-06-01 |
Pfizer Prod Inc |
Compuestos cristalinos novedosos
|
|
JP4505228B2
(ja)
*
|
2002-01-10 |
2010-07-21 |
バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト |
Ｒｈｏ−キナーゼ阻害剤
|
|
EP1470121B1
(en)
|
2002-01-23 |
2012-07-11 |
Bayer HealthCare LLC |
Pyrimidine derivatives as rho-kinase inhibitors
|
|
MXPA04007196A
(es)
|
2002-01-23 |
2005-06-08 |
Bayer Pharmaceuticals Corp |
Inhibidores de rho-quinasa.
|
|
GB0202679D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1388541A1
(en)
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
|
NZ539901A
(en)
|
2002-11-26 |
2007-09-28 |
Pfizer Prod Inc |
Method of treatment of transplant rejection
|
|
CA2543116A1
(en)
*
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
|
|
EP1689407A1
(en)
*
|
2003-11-25 |
2006-08-16 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
|
CN101693695A
(zh)
*
|
2004-03-30 |
2010-04-14 |
大正制药株式会社 |
嘧啶衍生物以及与其应用有关的治疗方法
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
MXPA06015237A
(es)
|
2004-06-29 |
2007-12-10 |
Amgen Inc |
Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
|
|
JP2008508358A
(ja)
|
2004-08-02 |
2008-03-21 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
WO2006091450A1
(en)
*
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
|
US8183248B2
(en)
|
2005-05-13 |
2012-05-22 |
Irm Llc |
Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
|
|
WO2007007919A2
(en)
|
2005-07-14 |
2007-01-18 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
ZA200802685B
(en)
|
2005-09-30 |
2009-10-28 |
Vertex Pharma |
Deazapurines useful as inhibitors of janus kinases
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
US20100273776A1
(en)
*
|
2006-03-29 |
2010-10-28 |
FOLDRx PHARMACEUTICALS, INC |
Inhibition of alpha-synuclein toxicity
|
|
DK3421471T3
(da)
|
2006-04-25 |
2021-06-14 |
Astex Therapeutics Ltd |
Purin- og deazapurinderivater som farmaceutiske forbindelser
|
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
|
AR064879A1
(es)
|
2007-01-12 |
2009-04-29 |
Astellas Pharma Inc |
Compuesto de piridina condensado
|
|
CN101679440A
(zh)
*
|
2007-04-02 |
2010-03-24 |
帕劳制药股份有限公司 |
作为jak3抑制剂的吡咯并嘧啶衍生物
|
|
KR20150036210A
(ko)
|
2007-06-13 |
2015-04-07 |
인사이트 코포레이션 |
야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
DE102007027800A1
(de)
|
2007-06-16 |
2008-12-18 |
Bayer Healthcare Ag |
Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
|
|
CA2705319C
(en)
*
|
2007-11-10 |
2019-01-15 |
Laurence Reid |
Systems and methods for workflow automation, adaptation and integration
|
|
EA019869B1
(ru)
*
|
2007-11-28 |
2014-06-30 |
Дана Фарбер Кансер Инститьют, Инк. |
Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
|
|
PE20091485A1
(es)
|
2008-02-06 |
2009-10-26 |
Novartis Ag |
DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
|
|
JP5368485B2
(ja)
*
|
2008-02-25 |
2013-12-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピロロピラジンキナーゼインヒビター
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
WO2009115084A2
(de)
*
|
2008-03-20 |
2009-09-24 |
Schebo Biotech Ag |
Neue pyrrolopyrimidin-derivate und deren verwendungen
|
|
US20110201599A1
(en)
*
|
2008-07-03 |
2011-08-18 |
Exelixis, Inc. |
CDK Modulators
|
|
JP2011529918A
(ja)
*
|
2008-08-01 |
2011-12-15 |
バイオクライスト ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ３阻害剤としてのピペリジン誘導体
|
|
KR101335843B1
(ko)
|
2008-08-20 |
2013-12-02 |
조에티스 엘엘씨 |
피롤로[2,3-ｄ]피리미딘 화합물
|
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
|
AU2010239396B2
(en)
|
2009-04-20 |
2016-06-23 |
Auspex Pharmaceuticals, Llc |
Piperidine inhibitors of Janus Kinase 3
|
|
SI2432472T1
(sl)
|
2009-05-22 |
2019-11-29 |
Incyte Holdings Corp |
3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
WO2011003418A1
(en)
|
2009-07-08 |
2011-01-13 |
Leo Pharma A/S |
Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
|
|
TWI466885B
(zh)
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EA021478B1
(ru)
|
2009-10-09 |
2015-06-30 |
Инсайт Корпорейшн |
ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
|
|
ES2426407T3
(es)
|
2009-10-15 |
2013-10-23 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
|
WO2011075334A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
MX2012009074A
(es)
|
2010-02-05 |
2012-08-23 |
Pfizer |
Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
|
|
EP2360158A1
(en)
*
|
2010-02-18 |
2011-08-24 |
Almirall, S.A. |
Pyrazole derivatives as jak inhibitors
|
|
EP3354652B1
(en)
|
2010-03-10 |
2020-05-06 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
US9586961B2
(en)
*
|
2010-07-09 |
2017-03-07 |
Leo Pharma A/S |
Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
PE20140146A1
(es)
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
|
US9233964B2
(en)
|
2011-01-07 |
2016-01-12 |
Leo Pharma A/S |
Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
CN103547580B
(zh)
|
2011-03-22 |
2016-12-07 |
阿迪维纳斯疗法有限公司 |
取代的稠合三环化合物、其组合物及医药用途
|
|
CN103502249A
(zh)
*
|
2011-05-17 |
2014-01-08 |
普林斯匹亚生物制药公司 |
作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
|
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
ES3018133T3
(en)
|
2011-11-30 |
2025-05-14 |
Univ Emory |
Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
|
|
PT2796460T
(pt)
*
|
2011-12-21 |
2018-11-05 |
Shanghai hengrui pharmaceutical co ltd |
Derivado pirrole de anel heteroarilo de seis membros, método de preparação do mesmo e suas utilizações médicas
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
CA2873967A1
(en)
|
2012-05-21 |
2013-11-28 |
Bayer Pharma Aktiengesellschaft |
Substituted benzothienopyrimidines
|
|
EP2867236B1
(en)
*
|
2012-06-29 |
2017-06-14 |
Pfizer Inc |
Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
|
|
DK2875013T3
(en)
*
|
2012-07-17 |
2018-01-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
INDOLECAR CARBON NITRILS AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
|
|
CN108354938A
(zh)
*
|
2012-07-20 |
2018-08-03 |
硕腾服务有限责任公司 |
Janus激酶（jak）抑制剂的给药方案
|
|
TW201412740A
(zh)
*
|
2012-09-20 |
2014-04-01 |
Bayer Pharma AG |
經取代之吡咯并嘧啶胺基苯并噻唑酮
|
|
US9593115B2
(en)
|
2012-09-21 |
2017-03-14 |
Advinus Therapeutics Ltd. |
Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
|
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
|
PH12020551186B1
(en)
|
2012-11-15 |
2024-03-20 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
KR101683061B1
(ko)
*
|
2013-02-07 |
2016-12-07 |
한국과학기술연구원 |
ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
|
|
GEP201606600B
(en)
|
2013-02-22 |
2017-01-10 |
Pfizer |
Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
|
|
RS62867B1
(sr)
|
2013-03-06 |
2022-02-28 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
|
WO2014139388A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
SMT202000315T1
(it)
|
2013-08-07 |
2020-07-08 |
Incyte Corp |
Forme di dosaggio a rilascio prolungato per un inibitore di jak1
|
|
SI3077395T1
(en)
|
2013-12-05 |
2018-03-30 |
Pfizer Inc. |
Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
|
|
EP3083618B1
(en)
|
2013-12-17 |
2018-02-21 |
Pfizer Inc |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
WO2016024185A1
(en)
|
2014-08-12 |
2016-02-18 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
EP3288943B1
(en)
|
2015-05-01 |
2022-09-28 |
Pfizer Inc. |
Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
|
|
KR102081272B1
(ko)
*
|
2015-05-29 |
2020-02-25 |
우시 포춘 파마슈티컬 컴퍼니 리미티드 |
Janus 키나아제 억제제
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
CN106831779B
(zh)
*
|
2015-11-28 |
2019-07-19 |
南昌弘益药业有限公司 |
一类jak激酶抑制剂的新化合物
|
|
EP3416965B1
(en)
|
2016-02-16 |
2020-10-07 |
Zoetis Services LLC |
Process for preparing 7h-pyrrolo [2,3-d]pyrimidine compounds
|
|
CN107098908B
(zh)
*
|
2016-02-23 |
2021-01-08 |
欣凯医药科技(上海)有限公司 |
一种吡咯并嘧啶类化合物的制备方法和应用
|
|
JP7116063B2
(ja)
|
2016-12-14 |
2022-08-09 |
インターベット インターナショナル ベー． フェー． |
選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
|
|
JP6944496B2
(ja)
|
2018-10-22 |
2021-10-06 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
|
|
BR112021008742A2
(pt)
*
|
2018-11-05 |
2021-08-10 |
Avista Pharma Solutions, Inc. |
compostos químicos
|
|
US11174263B2
(en)
|
2018-12-31 |
2021-11-16 |
Biomea Fusion, Inc. |
Inhibitors of menin-MLL interaction
|
|
SG11202106304RA
(en)
|
2018-12-31 |
2021-07-29 |
Biomea Fusion Llc |
Irreversible inhibitors of menin-mll interaction
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2020198583A1
(en)
|
2019-03-27 |
2020-10-01 |
Insilico Medicine Ip Limited |
Bicyclic jak inhibitors and uses thereof
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
MX2023007150A
(es)
|
2020-12-18 |
2023-09-04 |
Boehringer Ingelheim Animal Health Usa Inc |
Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
|
|
TW202320796A
(zh)
|
2021-08-11 |
2023-06-01 |
美商拜歐米富士恩股份有限公司 |
用於糖尿病的menin-mll相互作用之共價抑制劑
|
|
US12018032B2
(en)
|
2021-08-20 |
2024-06-25 |
Biomea Fusion, Inc. |
Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
|
|
WO2023029943A1
(zh)
*
|
2021-09-03 |
2023-03-09 |
星药科技(北京)有限公司 |
一种芳杂环化合物及其制备方法和用途
|
|
US20250051337A1
(en)
*
|
2021-09-28 |
2025-02-13 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
|
|
CN118541364A
(zh)
|
2021-12-24 |
2024-08-23 |
英特维特国际股份有限公司 |
氨基吡唑化合物的用途
|
|
GB202215132D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
GB202215117D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
WO2024155710A1
(en)
|
2023-01-18 |
2024-07-25 |
Biomea Fusion, Inc. |
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
|